Elsevier

The Lancet

Volume 356, Issue 9227, 29 July 2000, Pages 398-399
The Lancet

Research Letters
Opioid use in last week of life and implications for end-of-life decision-making

https://doi.org/10.1016/S0140-6736(00)02534-4Get rights and content

Summary

This study was prompted by public and professional concern that the use of opioids for symptom control might shorten life. We retrospectively analysed the pattern of opioid use in the last week of life in 238 consecutive patients who died in a palliative care unit. Median doses of opioid were low (26·4 mg) in the last 24 h of life and patients who received opioid increases at the end of life did not show shorter survival than those who received no increases. The doctrine of double effect therefore need not be invoked to provide symptom control at the end of life.

References (5)

  • PD Wall

    The generation of yet another myth on the use of narcotics

    Pain

    (1997)
  • R Gillon et al.

    When doctors might kill their patients

    BMJ

    (1999)
There are more references available in the full text version of this article.

Cited by (0)

View full text